Blog
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research
Anheuser-Busch Inbev (BUD) is a Top-Ranked Momentum Stock: Should You Buy?
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different
Rio Tinto vs. BHP Group: Which Mining Stock is the Better Buy Now?
Rio Tinto Group RIO and BHP Group Limited BHP are both familiar names operating in the Zacks Mining - Miscellaneous industry. As rivals, the companies are focused on the extraction of minerals
Baidu Set to Report Q4 Earnings: What's in Store for the Stock?
Baidu BIDU is scheduled to release fourth-quarter 2025 results on Feb. 26.The Zacks Consensus Estimate for Baidu’s fourth-quarter revenues is pegged at $4.68 billion, indicating growth of 0.15% on a
Why Aecom Technology (ACM) is a Top Growth Stock for the Long-Term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research
VALE S.A. (VALE) is a Top-Ranked Growth Stock: Should You Buy?
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The research service
Why Moelis (MC) is a Top Growth Stock for the Long-Term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research
Here's Why Transocean (RIG) is a Strong Growth Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research
Here's Why AbbVie (ABBV) is a Strong Growth Stock
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different
Why Sensata (ST) is a Top Growth Stock for the Long-Term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates
Why Nordson (NDSN) is a Top Growth Stock for the Long-Term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service
Why Jack Henry (JKHY) is a Top Growth Stock for the Long-Term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research
Why First American Financial (FAF) is a Top Growth Stock for the Long-Term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research
Why LATAM (LTM) is a Top Growth Stock for the Long-Term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different
Cognizant (CTSH) is a Top-Ranked Growth Stock: Should You Buy?
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different
Lumentum's OCS and CPO Momentum Builds: More Upside for the Stock?
Lumentum LITE is at an inflection point in two of the most strategically significant optical technologies powering the AI infrastructure buildout. Optical circuit switches (OCS) and co-packaged
Shoals Technologies Group (SHLS) Lags Q4 Earnings Estimates
Shoals Technologies Group (SHLS) came out with quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.08 per share a year ago
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates
Repligen (RGEN) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.44 per share a year ago. These figures
Is Monro Muffler Brake (MNRO) Outperforming Other Consumer Discretionary Stocks This Year?
Investors interested in Consumer Discretionary stocks should always be looking to find the best-performing companies in the group. Is Monro Muffler Brake (MNRO) one of those stocks right now? Let's
Are Investors Undervaluing Deluxe (DLX) Right Now?
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop
Here's Why Lear (LEA) is a Strong Value Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service
Why Envista (NVST) is a Top Value Stock for the Long-Term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different
Orthofix (OFIX) Q4 Earnings and Revenues Lag Estimates
Orthofix (OFIX) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.02 per share a year ago. These figures
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago. These
Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.29 per share. This compares to a loss of $0.12 per